The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XPO, IMMU, AXGN and AGN

Author's Avatar
Jan 24, 2019
Article's Main Image

NEW YORK, Jan. 23, 2019 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

XPO Logistics, Inc. (: XPO)
Class Period: February 26, 2014 to December 12, 2018
Lead Plaintiff Deadline: February 12, 2019

The lawsuit alleges XPO Logistics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) XPO’s highly touted aggressive M&A strategy had yielded only minimal returns to the Company; (ii) XPO was utilizing improper accounting practices to mask its true financial condition, including, inter alia, under-reporting of bad debts and aggressive amortization assumptions; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Get additional information about the XPO lawsuit: http://www.kleinstocklaw.com/pslra-1/xpo-logistics-inc-loss-submission-form?wire=3

Immunomedics, Inc. ( IMMU)
Class Period: August 23, 2018 to December 20, 2018
Lead Plaintiff Deadline: February 25, 2019

The complaint alleges that, throughout the class period, defendants made false and misleading statements. The United States Food & Drug Administration issued citations against Immunomedics for multiple violations at its Morris Plains, New Jersey facility. The FDA citations included the manipulation of bioburden samples, backdating of records, and misrepresentation of integrity test procedures. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. On December 17, 2018, FDAnews.com published an article entitled “FDA Hits Immunomedics for Data Integrity Breach.” Upon this news, Immunomedics’ stock price fell sharply, damaging investors.

Get additional information about the IMMU lawsuit: http://www.kleinstocklaw.com/pslra-1/immunomedics-inc-loss-submission-form?wire=3

AxoGen, Inc. ( AXGN)
Class Period: August 7, 2017 to December 18, 2018
Lead Plaintiff Deadline: March 11, 2019

The complaint alleges AxoGen, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company aggressively increased prices to mask lower sales; (2) the Company’s pricing alienated customers and threatened the Company’s future growth; (3) ambulatory surgery centers form a significant part of the market for the Company’s products; (4) such centers were especially sensitive to price increases; (5) the Company was dependent on a small number of surgeons whom the Company paid to generate sales; (6) the Company’s consignment model for inventory was reasonably likely to lead to channel stuffing; (7) the Company offered purchase incentives to sales representatives to encourage channel stuffing; (8) the Company’s sales representatives were encouraged to backdate revenue to artificially inflate metrics; (9) the Company lacked adequate internal controls to prevent such channel stuffing and backdating of revenue; (10) the Company’s key operating metrics, such as number of active accounts, were overstated; and (11) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Get additional information about the AXGN lawsuit: http://www.kleinstocklaw.com/pslra-1/axogen-inc-loss-submission-form?wire=3

Allergan plc (: AGN)
Class Period: May 9, 2017 to December 19, 2018
Lead Plaintiff Deadline: February 19, 2019

During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in Europe. On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the company's CE Mark for these products, and the stock price fell drastically following the news.

Get additional information about the AGN lawsuit: http://www.kleinstocklaw.com/pslra-1/allergan-plc-loss-submission-form?wire=3

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

ti?nf=NzQ5MjAzNyMyNzA0Njg1IzIwODM5NTE=